Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection.
We report a breast cancer patient with leptomeningeal carcinomatosis (LM) who showed an excellent objective and subjective response to letrozole, with a progression-free survival of 16 months. We think that despite the poor prognosis and short survival of patients with LM, early diagnosis and treatment with appropriate hormonal manipulation may improve the outcome and achieve prolonged palliation in selected hormone-positive breast cancer patients with LM. Possible clues predicting the response were also evaluated in the context of literature data.
Ozdogan
Mustafa
M
Division of Medical Oncology, Department of Internal Medicine, Akdeniz University Medical School, Antalya, Turkey. mustafa0051@hotmail.com
Samur
Mustafa
M
Bozcuk
Hakan S
HS
Sagtas
Ergin
E
Yildiz
Mustafa
M
Artac
Mehmet
M
Savas
Burhan
B
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000556:secondary*; D017024:Chemotherapy, Adjuvant; D016371:Cranial Irradiation; D005260:Female; D006801:Humans; D000077289:Letrozole; D008207:Lymphatic Metastasis; D008577:Meningeal Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D012074:Remission Induction; D017741:Survivors; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole